A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients with Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment

Wen Tsung Huang, Hong Hwa Chen, Chung Hung Yeh, Yin Che Lu, Wei Shou Hwang, Jen Seng Huang, Chou Pin Chen, Peng Chan Lin, Wu Ching Uen, Yang Cheng Lee, Hwei Ming Wang, Hong Cheng Wu, Jinn Shiun Chen, Ruey Ho Kao, Chi Chou Huang, Hao Hsuan Jeng, Chia Jung Lin, Ruey Kuen Hsieh

Research output: Contribution to journalArticle

1 Citation (Scopus)


Objective: This postmarketing surveillance study evaluated the safety and efficacy of cetuximab therapy in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in Taiwan. Methods: Patients with EGFR-expressing mCRC who had failed prior irinotecan-based chemotherapy and were receiving cetuximab therapy were monitored for treatment efficacy and safety from the time of first infusion until 28 days after the last infusion regardless of the reasons for discontinuation. The study followed 269 patients for approximately 2 years. Results: No unexpected adverse events associated with cetuximab therapy were reported, and most events were grade 1 or 2. The most common drug-related adverse events of any grade were rash (21.6%) and dermatitis acneiform (4.8%). Reported grade 3/4 events were rash (4.5%), dermatitis acneiform (0.4%), and diarrhea (0.4%). Cetuximab treatment for patients receiving second-/third-line (177 patients) or above therapy (92 patients) was associated with a median progressionfree survival time of 3.37 and 3.90 months, respectively, and a median overall survival time of 17.6 and 21.1 months, respectively. The response rates for the second-/third-line treatment and fourth-line or above cetuximab treatment groups were similar (21.5% vs 17.4%; P = 0.428). Conclusion: Cetuximab showed no unexpected safety findings and was efficacious in treating patients with EGFR-expressing mCRC in community practice in Taiwan.

Original languageEnglish
Pages (from-to)1108-1114
Number of pages7
JournalJournal of Investigative Medicine
Issue number7
Publication statusPublished - Jan 1 2013
Externally publishedYes



  • Cetuximab
  • KRAS
  • metastatic colorectal cancer
  • overall survival
  • progression-free survival
  • safety

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Huang, W. T., Chen, H. H., Yeh, C. H., Lu, Y. C., Hwang, W. S., Huang, J. S., Chen, C. P., Lin, P. C., Uen, W. C., Lee, Y. C., Wang, H. M., Wu, H. C., Chen, J. S., Kao, R. H., Huang, C. C., Jeng, H. H., Lin, C. J., & Hsieh, R. K. (2013). A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients with Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment. Journal of Investigative Medicine, 61(7), 1108-1114. https://doi.org/10.231/JIM.0b013e3182a6799d